MedTrace Logo

Methylphenidate Treatment of Cancer-Related Fatigue

NCT00758407 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2010-01-13

No results posted yet for this study

Summary

The purpose of this randomized controlled clinical trial is to investigate the efficacy and safety of methylphenidate in patients with fatigue caused by cancer.

Conditions

  • Cancer-related Fatigue

Interventions

DRUG

Methylphenidate hydrochloride

sustained release, dosage according to an individual titration schedule

DRUG

Placebo

dosage according to an individual titration schedule

Sponsors & Collaborators

  • Medice Arzneimittel Pütter GmbH & Co KG

    lead INDUSTRY

Principal Investigators

  • Manfred Heim, Prof. · Sonnenbergklinik, Hardstr. 13, D-37242 Bad Sooden-Allendorf

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00758407 on ClinicalTrials.gov